Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Debt to Equity (2020 - 2023)

C4 Therapeutics has reported Debt to Equity over the past 4 years, most recently at $0.04 for Q2 2023.

  • For Q2 2023, Debt to Equity rose 37.01% year-over-year to $0.04; the TTM value through Jun 2023 reached $0.04, up 37.01%, while the annual FY2022 figure was $0.04, 43.63% up from the prior year.
  • Debt to Equity for Q2 2023 was $0.04 at C4 Therapeutics, up from $0.04 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.04 in Q2 2023 and troughed at -$0.06 in Q3 2020.
  • A 4-year average of $0.03 and a median of $0.03 in 2022 define the central range for Debt to Equity.
  • On a YoY basis, Debt to Equity climbed as much as 141.91% in 2021 and fell as far as 22.8% in 2021.
  • Year by year, Debt to Equity stood at $0.04 in 2020, then fell by 22.8% to $0.03 in 2021, then skyrocketed by 43.63% to $0.04 in 2022, then grew by 11.4% to $0.04 in 2023.
  • Business Quant data shows Debt to Equity for CCCC at $0.04 in Q2 2023, $0.04 in Q1 2023, and $0.04 in Q4 2022.